transfusiontransmiss
tt
risk
associ
major
transfusionrelev
virus
hiv
low
last
year
grow
awar
threat
blood
safeti
emerg
infecti
diseas
number
known
potenti
transfus
transmiss
two
publish
model
estim
transfusiontransmiss
risk
eid
refer
biggerstaffpetersen
model
european
upfront
risk
assess
tool
eufrat
respect
appli
sever
eid
outbreak
situat
describ
compar
methodolog
principl
model
highlight
similar
differ
also
discuss
appropri
compar
result
two
model
quantit
tt
risk
eid
inform
decis
risk
mitig
strategi
costeffect
final
present
qualit
risk
assess
zika
viru
zikv
eid
agent
caus
sever
outbreak
sinc
latest
largest
ever
outbreak
sever
probabl
case
transfusiontransmiss
zikv
report
indic
transfusiontransmiss
therefor
risk
blood
safeti
discuss
quantit
model
tt
risk
zikv
current
problemat
crown
hepat
c
viru
hcv
reduc
low
probabl
achiev
combin
commun
educ
nonremuner
voluntari
blood
donat
predon
donor
questionnair
design
elicit
risk
behavior
univers
donor
screen
pathogen
inactiv
procedur
incorpor
product
plasmaderiv
product
avail
pathogen
reduct
technolog
fresh
blood
compon
addit
countri
perform
serolog
screen
treponema
pallidum
syphili
number
also
screen
antibodi
human
tcell
lymphotrop
viru
type
bacteri
contamin
platelet
compon
howev
last
year
increas
awar
threat
blood
safeti
emerg
infecti
diseas
eid
agent
review
provid
overview
eid
agent
defin
repres
potenti
risk
blood
safeti
differ
classic
transfusionrelev
agent
describ
compar
methodolog
principl
limit
two
model
develop
appli
estim
tt
risk
eid
agent
final
use
zika
viru
zikv
contemporari
case
studi
assess
risk
eid
agent
blood
safeti
wide
accept
definit
eid
whose
incid
human
increas
within
past
decad
threaten
increas
near
futur
perhap
necessarili
imprecis
definit
specifi
level
past
threaten
incid
increas
differenti
true
increas
incid
appar
increas
due
greater
awar
addit
take
account
geograph
variat
wherebi
eid
agent
may
emerg
one
region
establish
anoth
period
decad
somewhat
arbitrari
therefor
absenc
precis
univers
applic
definit
emerg
could
appli
infecti
diseas
region
basi
take
account
local
epidemiolog
caus
agent
eid
includ
new
previous
undetect
agent
well
known
agent
reemerg
follow
period
low
incid
diseas
associ
previous
recogn
import
class
novel
eid
human
zoonot
infect
driven
part
increas
human
demand
meat
anim
product
agent
cross
speci
barrier
human
subsequ
transmiss
may
enhanc
number
factor
predomin
relat
human
activ
fig
eid
new
phenomenon
frequenc
report
outbreak
increas
last
year
expert
predict
continu
emphas
point
list
centuri
outbreak
alreadi
includ
addit
ongo
outbreak
west
nile
viru
wnv
sever
acut
respiratori
syndrom
corona
viru
sarscov
china
reemerg
avian
influenza
viru
chikungunya
viru
chikv
la
reunion
island
follow
western
pacif
region
america
influenza
viru
middl
east
respiratori
syndrom
corona
viru
merscov
middl
east
influenza
viru
china
zikv
yap
western
pacif
region
america
ebola
viru
ebov
west
africa
blood
safeti
perspect
number
eid
agent
known
potenti
transfusiontransmiss
base
follow
criteria
abl
establish
infect
human
spread
within
popul
infect
includ
asymptomat
blood
phase
abl
surviv
blood
process
storag
transmiss
intraven
rout
associ
clinic
appar
diseas
least
proport
recipi
major
transfusionrelev
virus
eid
agent
differ
eid
agent
typic
less
well
character
major
transfusionrelev
virus
note
either
newli
identifi
known
time
consid
research
prioriti
therefor
eid
outbreak
typic
difficult
predict
risk
assess
often
high
degre
uncertainti
major
transfusionrelev
virus
transmit
humantohuman
without
vector
host
reservoir
endem
worldwid
distribut
number
eid
agent
known
transfusiontransmiss
includ
dengu
viru
denv
west
nile
viru
wnv
plasmodium
spp
trypanosoma
cruzi
primarili
vectorborn
defin
geograph
distribut
due
focu
major
transfusionrelev
virus
sensit
specif
assay
univers
donor
screen
develop
implement
countri
tt
risk
estim
risk
model
contrast
donor
screen
possibl
eid
agent
suitabl
assay
develop
approv
limit
number
agent
includ
wnv
cruzi
hepat
viru
hav
human
parvoviru
primat
erythroparvoviru
denv
plasmodium
spp
moreov
even
suitabl
assay
avail
eid
agent
univers
donor
screen
alway
implement
may
mandat
consid
proportion
respons
perceiv
level
risk
feasibl
due
inadequ
resourc
estim
tt
risk
pathogen
import
part
overal
risk
assess
risk
estim
necessarili
includ
measur
uncertainti
nonetheless
provid
indic
risk
level
turn
use
inform
decis
implement
risk
mitig
strategi
classic
transfusionrelev
virus
univers
screen
implement
estim
tt
risk
well
establish
use
model
base
two
key
paramet
incid
infect
donor
popul
known
due
univers
donor
screen
infecti
window
period
period
acut
infect
donor
may
infecti
detect
screen
assay
howev
model
base
incidentwindow
period
methodolog
applic
eid
agent
donor
screen
implement
incid
infect
donor
popul
known
assay
window
period
applic
therefor
altern
risk
model
develop
includ
estim
eid
incid
blood
donor
popul
base
observ
ie
report
incid
gener
popul
first
publish
model
estim
tt
risk
eid
agent
develop
biggerstaff
petersen
bp
model
respons
wnv
outbreak
us
first
report
queen
new
york
citi
wnv
mosquitoborn
flaviviru
tt
well
document
prior
implement
donor
screen
wnv
biggerstaff
petersen
retrospect
estim
tt
risk
wnv
outbreak
queen
subsequ
region
us
bp
model
use
report
incid
wnv
neurolog
diseas
wnnd
deriv
estim
incid
asymptomat
infect
gener
popul
turn
use
estim
proport
donor
asymptomat
viraem
base
number
assumpt
tabl
estim
proport
asymptomat
viraem
donor
equat
risk
infect
donat
enter
blood
suppli
turn
interpret
tt
risk
develop
bp
model
includ
statist
resampl
method
mont
carlo
simul
estim
proport
popul
asymptomat
viraem
point
time
formula
estim
averag
proport
asymptomat
viraem
donor
specifi
time
period
recent
shang
et
al
develop
hybrid
approach
bp
model
combin
statist
resampl
formula
methodolog
perform
statist
resampl
requir
input
variabl
base
local
outbreak
data
number
report
case
wnnd
meningoenceph
period
observ
date
symptom
onset
report
case
popul
outbreak
area
addit
number
variabl
deriv
publish
histor
data
also
requir
time
cours
wnv
viraemia
ratio
wnnd
case
total
number
wnv
infect
ratio
asymptomaticsymptomat
infect
base
symptom
onset
date
report
wnnd
case
statist
resampl
simul
number
symptomat
viraem
case
time
base
rang
possibl
viraem
period
prior
subsequ
symptom
onset
base
size
gener
popul
ratio
total
wnv
infectionsreport
wnnd
case
assumpt
infect
donor
develop
symptom
risk
donat
prior
symptom
onset
model
deriv
risk
curv
repres
estim
proport
asymptomat
case
popul
equat
tt
risk
wnv
author
also
develop
methodolog
simpler
formula
estim
averag
wnv
tt
risk
specifi
time
period
provid
compar
estim
subsequ
appli
number
publish
studi
tabl
bp
formula
conceptu
express
asym
mean
durat
asymptomat
viraemia
take
account
asymptomat
viraem
period
proport
case
develop
clinic
symptom
entir
viraem
period
proport
develop
clinic
symptom
presymptomat
viraem
period
period
observ
r
ratio
total
infectionsreport
case
p
popul
incid
report
ie
symptomat
infect
first
term
repres
risk
infect
donor
present
donat
asymptomat
viraem
product
second
third
term
repres
incid
infect
develop
symptom
remain
asymptomat
formula
express
averag
risk
pr
collect
viraem
donat
asympomatit
infect
donor
incid
infect
therefor
bp
formula
averag
risk
estim
risk
collect
infecti
donat
asymptomat
infect
donor
period
observ
sinc
origin
applic
wnv
outbreak
us
bp
model
use
estim
tt
risk
denv
australia
outbreak
chikv
la
reunion
island
thailand
itali
hepat
viru
hav
latvia
ross
river
viru
rrv
australia
tabl
studi
bp
formula
averag
risk
defin
time
period
use
rather
statist
resampl
approach
presum
due
least
part
former
comput
simpler
requir
exact
date
symptom
onset
report
case
studi
show
bp
model
appli
rang
eid
agent
demonstr
regular
risk
model
across
region
provid
indic
chang
risk
level
time
geograph
therebi
inform
decis
regard
implement
risk
mitig
strategi
european
centr
diseas
prevent
control
ecdc
also
develop
model
estim
tt
risk
eid
agent
refer
european
upfront
risk
assess
tool
eufrat
eufrat
webbas
interfac
state
aim
assess
quantifi
tt
risk
eid
ongo
outbreak
input
paramet
requir
model
often
well
defin
contribut
inher
uncertainti
model
perform
statist
resampl
bp
model
date
symptom
onset
report
incid
case
requir
bp
model
take
account
reduct
tt
risk
relat
effici
transmiss
transfus
pathogen
reductioninactiv
due
blood
process
storag
recipi
immun
number
paramet
eufrat
model
includ
differ
risk
infect
donor
gener
popul
proport
symptomat
case
gener
popul
seek
health
care
misdiagnos
tt
effici
infect
end
product
level
immun
gener
popul
typic
unknown
eid
agent
section
describ
conceptu
basi
eufrat
report
applic
provid
compar
analysi
bp
model
eufrat
consid
risk
transmit
eid
agent
recipi
seri
risk
begin
risk
blood
donor
becom
infect
depend
upon
input
variabl
group
methodolog
eufrat
divid
logic
sequenc
four
five
step
associ
risk
descript
eufrat
consid
process
outlin
eufrat
user
manual
first
step
estim
risk
donor
infecti
time
donat
assum
proport
preval
infect
gener
popul
risk
function
length
infecti
period
includ
correct
factor
differ
risk
donor
becom
infect
compar
gener
popul
known
proport
undetect
case
donor
return
outbreak
area
risk
infect
proport
infect
incid
outbreak
area
durat
visit
risk
infect
donor
remain
infecti
time
donat
invers
proport
durat
period
leav
outbreak
area
time
donat
second
step
estim
number
donat
deriv
infecti
donor
incorpor
preval
infect
donor
popul
step
mean
donat
frequenc
probabl
infect
donor
interdict
predon
assess
procedur
third
step
estim
number
infect
donat
releas
process
blood
compon
infect
end
product
base
pathogen
remov
inactiv
due
blood
process
procedur
implement
effect
donor
screen
pathogen
reduct
technolog
final
step
estim
risk
recipi
becom
infect
follow
transfus
depend
tt
effici
agent
proport
recipi
immun
agent
addit
eufrat
option
defin
input
paramet
either
fix
valu
distribut
valu
latter
allow
paramet
uncertainti
use
montecarlo
simul
determin
valu
paramet
repeat
random
sampl
triangular
distribut
defin
plausibl
rang
enter
user
eufrat
use
number
report
studi
estim
tt
risk
chikv
denv
coxiella
burnetii
rrv
tabl
origin
descript
eufrat
investig
retrospect
appli
chikv
outbreak
emiliaromagna
region
northeast
itali
result
demonstr
final
estim
risk
transmit
infect
recipi
substanti
less
estim
risk
asymptomat
infect
blood
donor
exampl
base
estim
weekli
donor
preval
chikv
case
per
ci
donor
outbreak
peak
actual
risk
sever
infect
recipi
estim
per
donat
tt
risk
typic
express
risk
transmit
infect
regardless
clinic
outcom
specif
report
author
eufrat
also
use
nonoutbreak
area
estim
tt
risk
associ
donor
return
outbreak
area
extend
retrospect
estim
tt
risk
outbreak
period
subsequ
futur
risk
associ
donor
potenti
remain
infecti
time
follow
end
outbreak
bp
eufrat
model
base
number
assumpt
summar
tabl
particular
number
assumpt
requir
estim
eid
incid
elig
donor
popul
base
incid
gener
popul
import
part
model
firstli
diagnosi
report
symptomat
infect
gener
popul
repres
symptomat
case
secondli
publish
histor
data
estim
ratio
asymptomaticsymptomat
infect
applic
studi
popul
ratio
import
allow
total
incid
symptomat
asymptomat
gener
popul
estim
incid
report
symptomat
infect
thirdli
individu
symptomat
infect
would
either
present
donat
would
exclud
donat
bp
model
assumpt
basi
determin
period
infect
ross
river
viru
rrv
australia
appli
eufrat
biggerstaffpetersen
model
demonstr
tempor
geograph
variat
risk
donor
atrisk
present
donateth
entir
viraem
period
donor
remain
asymptomat
presymptomat
period
develop
symptom
fourthli
blood
donor
risk
infect
gener
popul
therefor
incid
infect
blood
donor
popul
gener
popul
section
discuss
valid
compar
outcom
bp
eufrat
model
note
three
import
methodolog
differ
two
model
alreadi
note
bp
eufrat
model
estim
risk
asymptomat
infect
donor
howev
eufrat
incorpor
addit
risk
compon
risk
collect
infecti
donat
step
blood
productrel
risk
step
recipientrel
risk
step
bp
model
step
eufrat
methodolog
similar
assumpt
discuss
made
worth
note
assumpt
often
applic
eid
outbreak
assum
donor
risk
infect
gener
popul
period
infecti
less
period
observ
step
eufrat
express
p
preval
infecti
donor
p
number
report
infect
popul
n
size
popul
proport
undetect
infect
also
assum
report
system
effect
ie
symptomat
case
report
effect
proport
asymptomat
infect
proport
detect
ie
symptomat
donor
ratio
total
infect
symptomat
infect
ipn
incid
report
symptomat
case
dt
proport
observ
period
donor
infecti
ie
risk
give
infecti
donat
therefor
equat
express
assum
infect
includ
chronic
phase
donor
test
implement
preval
asymptomat
infect
donor
p
would
therefor
interdict
applic
base
assumpt
eufrat
estim
preval
infecti
donor
screen
andor
test
fact
estim
preval
asymptomat
infecti
donor
remain
asymptomat
cours
infect
therefor
eufrat
model
exclud
risk
associ
asymptomat
donor
subsequ
develop
symptom
ie
presymptomat
infecti
period
repres
second
differ
bp
eufrat
model
bp
model
incorpor
risk
associ
presymptomat
infecti
period
consequ
eufrat
model
could
potenti
underestim
risk
asymptomat
infect
donorsth
higher
proport
asymptomat
infect
subsequ
develop
symptom
greater
underestim
step
third
differ
bp
eufrat
model
relat
distribut
input
paramet
may
potenti
contribut
output
differ
note
bp
model
use
mont
carlo
simul
base
assum
distribut
presymptomat
viraem
period
durat
entir
viraem
period
eufrat
also
use
mont
carlo
simul
defin
triangular
distribut
input
paramet
wherebi
uncertainti
incid
preval
estim
account
sampl
beta
distribut
would
expect
affect
uncertainti
estim
lesser
impact
mean
median
estim
risk
due
methodolog
differ
would
expect
even
use
data
set
would
differ
risk
estim
deriv
two
model
although
differ
minim
assumpt
note
made
direct
comparison
tt
risk
estim
bp
model
eufrat
report
three
eid
outbreak
either
differ
investig
separ
studi
investig
part
singl
studi
use
data
set
input
paramet
model
appli
chikv
outbreak
itali
q
fever
outbreak
netherland
similar
risk
estim
outbreak
third
studi
compar
eufrat
bp
model
perform
rrv
australia
also
use
data
set
input
paramet
model
unlik
previou
exampl
rrv
model
show
appear
substanti
differ
risk
estim
eufrat
bp
model
exampl
eufrat
estim
risk
asymptomat
infect
donor
ie
risk
collect
viraem
donat
state
western
australia
period
june
may
ci
compar
bp
model
estim
risk
collect
viraem
donat
uncertainti
rang
differ
risk
estim
may
due
methodolog
differ
model
note
bp
model
perform
use
plausibl
lower
upper
point
estim
viraem
period
asymptomaticsymptomat
infect
ratio
eufrat
model
estim
base
assum
distribut
paramet
addit
unlik
bp
model
eufrat
take
account
presymptomat
viraem
period
proport
infect
develop
clinic
symptom
howev
note
plausibl
estim
bp
model
within
ci
eufrat
estim
indic
risk
estim
significantli
differ
zikv
latest
eid
agent
recogn
potenti
global
health
threat
driven
unpreced
ongo
outbreak
america
evid
zikv
caus
agent
number
neurolog
disord
includ
microcephali
newborn
februari
concern
culmin
declar
zikv
outbreak
brazil
constitut
public
health
emerg
intern
concern
zikv
mosquitoborn
flaviviru
first
isol
rhesu
monkey
zika
forest
uganda
first
isol
human
nigeria
zikv
outbreak
yap
island
major
outbreak
report
howev
number
zikv
outbreak
sinc
dramat
demonstr
outbreak
potenti
viru
first
report
outbreak
occur
yap
island
estim
case
follow
outbreak
french
polynesia
may
estim
case
may
subsequ
spread
western
pacif
region
earli
zikv
outbreak
report
america
remain
ongo
becom
largest
ever
report
outbreak
novemb
countri
exclud
us
mainland
america
report
activ
zikv
transmiss
march
total
suspect
confirm
zikv
case
report
pan
american
health
organ
america
case
local
acquir
zikv
report
us
mainland
recent
outbreak
outsid
africa
transmiss
believ
primarili
humanmosquitohuman
cycl
aegypti
primari
mosquito
vector
howev
nonvectorborn
mode
transmiss
report
sexual
includ
male
male
femal
male
perinat
intrauterin
breast
feed
blood
transfus
ongo
outbreak
zikv
america
rais
concern
potenti
risk
blood
safeti
firstli
note
zikv
demonstr
abil
establish
infect
human
spread
within
human
popul
secondli
estim
zikv
infect
develop
symptom
symptomat
infect
includ
presymptomat
viraem
period
although
viraem
period
appear
typic
brief
rel
low
level
viru
addit
zikv
rna
detect
asymptomat
blood
donor
outbreak
french
polynesian
puerto
rico
april
martiniqu
januari
june
continent
us
may
octob
thirdli
gener
consensu
zikv
caus
agent
sever
neurolog
disord
includ
microcephali
newborn
syndrom
gb
wider
popul
fourthli
evid
zikv
transfusiontransmiss
least
four
probabl
tt
case
report
brazil
current
outbreak
therefor
suffici
evid
zikv
transfusiontransmiss
eid
agent
similar
phylogenet
relat
denv
wnv
howev
accur
model
tt
risk
zikv
current
problemat
due
uncertainti
associ
requir
input
paramet
knowledg
zikv
tt
risk
model
publish
date
fig
summar
basi
paramet
uncertainti
nonetheless
respons
grow
evid
zikv
repres
threat
blood
safeti
number
jurisdict
implement
risk
mitig
strategi
precautionari
preemptiv
approach
even
though
risk
estim
formal
model
exampl
follow
us
food
drug
administr
fda
approv
use
two
investig
blood
donor
screen
assay
zikv
nucleic
acid
test
nat
investig
new
drug
applic
ind
subsequ
issu
guidanc
industri
recommend
implement
either
univers
screen
donat
us
zikv
individu
donat
id
nat
pathogen
reduct
technolog
platelet
plasma
note
guidanc
issu
without
formal
risk
assess
without
stakehold
consult
although
zikv
outbreak
america
declin
viru
remain
endem
mani
countri
previous
report
futur
epidem
outbreak
exclud
therefor
research
requir
improv
understand
zikv
epidemiolog
virolog
turn
provid
basi
reliabl
tt
risk
model
expert
consensu
correct
eid
outbreak
continu
occur
cours
centuri
pose
ongo
challeng
respons
maintain
safeti
blood
suppli
health
author
abl
anticip
respond
quickli
eid
outbreak
potenti
threat
blood
safeti
intens
ongo
surveil
epidemiolog
model
risk
assess
essenti
model
tt
risk
eid
agent
import
part
risk
assess
inform
decis
regard
risk
mitig
strategi
implement
strategi
appropri
review
describ
methodolog
principl
two
publish
model
estim
tt
risk
eid
agent
understand
methodolog
underpin
model
assist
investig
appli
specif
eid
outbreak
interpret
uncertainti
associ
risk
estim
author
declar
conflict
interest
none
